# Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial

> **NCT03173976** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Mohammed Milhem** · enrollment: 17 (actual)

## Conditions studied

- Chondrosarcoma

## Interventions

- **DRUG:** Zoledronic Acid

## Key facts

- **NCT ID:** NCT03173976
- **Lead sponsor:** Mohammed Milhem
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-07-18
- **Primary completion:** 2023-04-20
- **Final completion:** 2028-05-01
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2025-11-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03173976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03173976, "Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03173976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*